Advent International, a private equity investor, announced the launch of Cohance Lifesciences on Tuesday, a new brand identity for its API (active pharmaceutical ingredient) and CDMO (contract development and manufacturing company) platform.
Cohance Lifesciences stated in a release that it would assist in the creation of a unified new brand identity for the API and CDMO platform in order to better reflect its vision and operating philosophy.
Advent’s three portfolio companies, RA Chem Pharma, ZCL Chemicals, and Avra Laboratories, will form the platform.
According to the company, the Cohance Lifesciences platform is forward-integrated into pellets, formulations, and clinical research to provide end-to-end offerings to its customers.
Advent International intends to add more assets to the platform in the future as it strives to become one of India’s top three merchant API and CDMO companies.
Advent has been investing in India since 2007, and its Mumbai office was established in 2009. In October 2020, it entered the API space by acquiring a controlling stake in RA Chem Pharma. Later, in March 2021, the investor acquired control of ZCL Chemicals, and in April 2022, Avra Laboratories. Bharat Serums and Vaccines are two of its previous healthcare investments in India.
Advent has invested or committed more than $3.4 billion in 14 companies with headquarters or operations in India, including businesses and financial services, retail, consumer and leisure, healthcare, industrial, and technology. Advent has invested over $10.4 billion in healthcare across 51 companies globally.
Categories: Other News